Policy / Pricing FDA accelerated approval path needs improvement, says ICER PharmaphorumThe FDA's accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.Policy / PricingRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER. Policy / PricingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly says Foundayo safety confirmed in ACHIEVE-4 trialNext: Obesity’s explosive growth continues as Q1 deals exceed total 2025 value Related Stories Policy / Pricing US launches probe of German ‘underpayment’ for medicines pharminent June 19, 2026 Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026 Policy / Pricing German said to be backtracking on pharma rebate changes pharminent June 16, 2026
